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Background: Cilostazol may reduce angiographic late loss in drug-eluting stent (DES) as suggested by a few studies. However, it is unclear whether 
this anti-proliferative effect of cilostazol is generalizable to the different types of DES.
Methods: Total 960 patients with de novo coronary artery disease undergoing drug-eluting stent implantation (DES) were enrolled and randomized 
after coronary angiography to dual antiplatelet therapy (DAT) versus triple antiplatelet therapy (TAT). Cilostazol was administered on top of DAT for 6 
months to patients who were randomized to TAT group. Successful PCI and follow-up was done in 915 patients. The angiographic outcome compared 
is in-stent late loss according to antiplatelet regimen (DAT vs. TAT) and the type of stent (PES vs. ZES).
Results: Follow-up angiography was performed in 745 patients (male sex 88.0%, diabetes mellitus 33.3%, and age 62.6±9.4 years) with 1108 
(PES 567 / ZES 541) lesions. Median follow-up duration was 6.0 months and follow-up rate was 88.2%. Baseline demographic and angiographic 
characteristics were not significantly different between DAT and TAT. In-stent late loss was reduced by TAT with statistical significance (DAT 
0.62±0.52mm vs TAT 0.54±0.48mm, p=0.007). Target lesion revascularization rate was also mildly reduced by TAT, which did not reach the statistical 
significance (DAT 9.3% vs. TAT 7.5%, p=0.39). In subgroup analysis, the beneficial effect of cilostazol on the angiographic outcome was more 
pronounced in patients with ZES than PES or in non-diabetic than diabetic (DM) patients (Figure 1). In the multivariate analysis, the independent 
predictors of high in-stent late loss were ZES, DM, and non-prescription of cilostazol.
Conclusion: The use of cilostazol on top of DAT was associated with more favorable angiographic outcome in patients treated with DES. However, 
the degree of benefit seems to be different depending on the characteristics of patient or stent type. Further studies are warranted to clarify this 
differential effect of cilostazol.
